Photo illustration: Axios Visuals. Photo: Courtesy of BillionToOne
BillionToOne, a molecular diagnostics company focused on prenatal and cancer screening, saw its share price pop more than 80% on its first day of trading Thursday.
By the numbers: Joining a growing group of 2025 biotech IPOs, BillionToOne priced at $60, opened at $95 and traded as high as $123 before closing at $108.94 Thursday afternoon.
In an interview with Axios Pro, CEO Oguzhan Atay says the company started the IPO process about six months ago.
